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1. Introduction 
Neovascular Age Related Macular Degeneration (nAMD) has been a therapeutic challenge 
until recently. The natural course of the disease leads to a great deterioration of visual acuity 
and is considered to be the leading cause of legal blindness in people 50 years of age or 
older, especially in the Western countries.   
Until the end of the last century, no intervention could alter the natural history of the 
disease. Only in the last few decades, the retina specialists began to intervene in order to 
minimize the visual loss in those patients. Last ten years have been especially exciting as the 
new treatment modalities emerged and for the first time we could not only halt the 
progression of the deterioration, but rather improve vision in some patients.  
In this chapter we will present therapeutic modalities which were applied chronologically 
and then we will present the up to date treatment options. Finally we will briefly summarize 
new emerging drugs which are still under clinical evaluation.  
2. Past treatments  
2.1 Laser photocoagulation 
The first major clinical trial evaluating laser photocoagulation in treatment of nAMD was 
performed in the 1980-ies, at times when no treatment modality could change natural course 
of this disease. However, the Macular Photocoagulation Study (MPS) (1), which took 5 years 
to complete, demonstrated that argon laser photocoagulation could postpone or even 
prevent significant visual loss in patients with juxtafoveol and extrafoveol choroidal  
neovascular membranes (CNV). 
It was later shown that some benefits of reducing the damage generated by the natural 
course of the disease could be achieved by performing laser treatment on subfoveol CNV as 
well (2). As the reduction of visual acuity occurred immediately after the laser treatment, 
patients’ dissatisfaction became a major issue. 
2.2 Photodynamic therapy  
Photodynamic therapy (PDT) represented the first specific treatment option in treating 
nAMD and the treatment protocol consisted of intravenous application of a photosensitive 
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drug verteporfin, which was then activated by a 693-nanometer-long, verteporfin-sensitive 
laser beam light. 
Verterporfin activation was followed by a series of photochemical reactions, resulting in 
destruction and thrombosis of endothelial cells in the neovascular membrane complex (3). 
The PDT had a double selectivity mechanism: 
1. Verteporfin was utilized only by cells with accelerated metabolism (neovascular 
membrane), 
2. Laser beam was applied only to the area of CNV. 
With verteporfin accumulating itself selectively within the neovascular complex, the 
collateral damage to surrounding healthy tissue was minimal. Verteporfin was in circulation 
carried by plasma lipoproteins, which were utilized by endothelial cells due to accelerated 
metabolism of neovascular complex. Within the area illuminated by the laser beam, short-
acting free oxygen radicals induced endothelial cell damage, which process occurred 
through lipo  and cyclooxigenase modulated pathways, the final result being trombocyte 
aggregation and vasoconstriction of neovascular complex vessels (4). The slow metabolism 
of normal blood vessels made the utilization of verteporfin-carrying lipoproteins in normal 
vessels slow as well. Verterporfin was utilized by neovascular complex vessels within 15 
minutes. It took 30 minutes for normal blood vessels to utilize verteporfin. Therefore, the 
laser beam of 90 seconds duration must had been applied to the neovascular membrane no 
later than 30 minutes after the infusion was started, in order to prevent damage to normal 
blood vessels. The exact size and location of neovascular complex was determined by 
fluorescein angiography, which was a precondition to laser application. 
Treatment of AMD with Photodynamic Therapy (TAP) study (5) was a double blind placebo 
controlled randomized clinical trial evaluating the efficacy of PDT in treatment of minimally 
classic CNV. 609 patients were enrolled (402 in the verteporfin group and 207 in the placebo 
group). The treatment was repeated every 3 months in case of relapse of leakage or 
continuous leakage, which was confirmed by fluorescein angiography. At 12 month follow-
up 61.2% of patients from the verteporfin group, compared to 46.4% patients from the 
placebo group lost less than 3 logMar lines (minimal angle resolution logarithm) or 15 letters 
which was statistically significant. At 24 months follow-up, 213 (53%) patients from the 
verteporfin group, compared to 78 (38%) patients from the placebo group lost fewer than 3 
lines (6). The mean visual acuity was 1.3 lines better in the verteporfin group. The eyes 
treated with verteporfin had a 16% better chance for visual improvement by 1 or more lines, 
compared to the placebo group. The benefits of the verteporfin treatment were higher in 
case of the predominantly CNV (at least 50% of the neovascular complex has a classic 
component): 33% of patients from the verteporfin group lost 3 or more lines, compared to 
61% of patients from the placebo group after 12 months. If CNV was completely classic, the 
results were even better: 23% of patients from the verteporfin group lost fewer than 3 lines, 
whereas in the placebo group, 73% of patients lost 3 or more lines. 
In case of the minimally classic type of the CNV, results were however modest - positive 
effects of the treatment were noticed only if the maximal diameter of neovascular lesion was 
smaller than 4 disc diameters. The efficacy of the PDT for the minimally classic CNV with 
the greatest diameter of lesion up to 6 discs was later confirmed by the VIM study 
(Verteporfin Therapy of Subfoveal Minimally Classic CNV in AMD) (7). 
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The VIP study (Verteporfin in Photodynamic Therapy) evaluated PDT in patients with 
occult CNV and showed that 121 (54%) patients from the verteporfin group lost fewer than 
15 letters during 24 months of the follow-up, compared to 76 (67%) patients from the control 
group (8), whereby the best results were displayed by the patients with lesions smaller than 
4 disc diameters or with the initial visual acuity better than 20/50 (9). 
The mentioned studies demonstrated the efficacy of the PDT with verteporfin in 
maintaining the visual acuity or slowing down visual loss. It was the very first time that we 
could positively interfere with the natural course of the disease using PDT. 
2.3 Surgical treatment 
Surgical techniques in treatment of nAMD included submacular surgery, macular 
translocation, and submacular hemorrhage displacement. 
Macular translocation was a surgical procedure involving the detachment of the retina along 
with macula in order to move or translocate fovea from the diseased RPE onto healthy RPE. 
Although there had been reports of case series with quite good visual outcomes after the 
surgery, severe complications could arise during the process of retinal displacement (10,11). 
Therefore nowadays macular translocation may not be considered for most patients with 
nAMD given the treatment options already available. In the anti-VEGF era macular 
translocation may be employed in patients either with very advanced AMD or in those 
patients with disease recalcitrant to anti-VEGF therapy.  
Unfortunately the surgery undertaken in a very advanced cases wouldn’t result in 
significant improvement of vision as the degenerative process had already damaged the 
retinal macular tissue along with the diseased underlying RPE: but retina specialist are 
reluctant to recommend macular translocation at the stage of the disease while macular 
retina is still viable at which point macular translocation would result in better functional 
outcome. 
The full macular translocation surgery involved a detachment of the entire retina from the 
RPE by subretinal infusion of balanced saline solution fluid via 40 gauge needle with 360 
degrees circumferential retinotomy followed by the retinal rotation under perflorocarbon 
liquid during which process macula was displaced onto healthy RPE. The site of the 360 
retinotomy and the holes artificially created for detaching retina were sealed by endolaser 
photocoagulation. Then an exchange between perflorocarbon liquid with silicone oil was 
performed. After 3 months silicone oil was removed. 
3. Current treatment options 
3.1 Anti-VEGF drugs 
3.1.1 Pegaptanib sodium 
An additional step forward was made by introducing the anti-VEGF drugs as a treatment 
option for nAMD. Pegaptanib sodium (Macugen) was actually a synthetically derived 
polyonucleotide ligand binding specifically to VEGF-A 165 isoform.  The affinity to only one 
isoform of VEGF cluster explained pegaptanib sodium inferior therapeutic effect, compared 
to non-selective infibitors of all VEGF isoforms. 
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Data from VISION trial indicated that 70% of the treated patients with intravitreal 
pegaptanib sodium given on a 6-week basis lost fewer than 15 letters during a 24 month 
follow-up, compared to 55% of patients from the placebo group. The mean visual acuity 
decreased by 8 letters during the follow-up period in the patients treated with intravitreal 
pegaptanib sodium in this study (12). 
3.1.2 Ranibizumab 
Ranibizumab is a humanized antigen-binding FAB fragment monoclonal antibody towards 
human VEGF-A, derived from rodents. It is produced by recombinant technology from 
Escherichiae coli, with molecular weight of 48 kilodaltons. Ranibizumab inhibits all VEGF-A 
isoforms. Furthermore, it penetrates well through all layers of retina up to choroidea. The 
binding affinity of ranibizumab is 5-20 times higher comparing to bevacizumab(13). 
Ranibizumab was approved for intravitreal application in 2006. 
A large multicentric randomized clinical trial MARINA (Ranibizumab in Treatment of 
Occult and Minimally Classic CNV)(14) and ANCHOR (Ranibizumab in Treatment of 
Predominantly Classic CNV)(15) confirmed that ranibizumab, given on a monthly basis 
substantially improved visual acuity compared to placebo. The MARINA study enrolled 716 
patients and evaluated the efficacy of monthly ranibizumab (0.3mg and 0.5 mg), versus 
placebo given for 24 months. In the ranibizumab groups over 90% of patients lost fewer than 
15 letters (or 3 lines) compared to 62% patients from the placebo group. One third of 
patients from the ranibizumab group (0.5mg) gained 15 letters or more, while in the placebo 
group only 5% of patients achieved this effect. This was a significant breakthrough 
compared to all previous treatment options. Mean visual acuity improved by 7.2 letters 
(about 1 line of logMAR) at 12 month follow-up in the ranibizumab group (0.5mg), while in 
the placebo group, the visual acuity deteriorated by more than 10 letters. The benefit in 
visual acuity was maintained at 24 months.  During 24 months, presumed endophthalmitis 
was identified in five patients (1.0%) and serious uveitis in six patients (1.3%). 
The ANCHOR study enrolled 423 patients and compared the efficacy and safety of 
ranibizumab given on a monthly basis with standard PDT with verteporfin. The follow-up 
period was 24 months. At the end of the study, over 90% of patients from the ranibizumab 
group and 65% of patients from the photodynamic group lost fewer than 15 letters. 
Furthermore, over one third of patients from the ranibizumab group gained 15 letters or 
more, compared to 5.6% of patients from the PDT group. Mean visual acuity improved by 
11.3 letters in the ranibizumab group (0.5mg), whereas patients from the photodynamic 
group had mean decrease of 9.5 letters. Reduction in central retinal thickness, measured by 
OCT, was also observed through the follow-up. 
Endophthalmitis or serious uveitis occurred in around 2% of patients from the ranibizumab 
group (0.5 mg). Even though visual results were good, it took 24 injections over 2 year 
period to achieve it. Several studies were conducted in order to see whether a number of 
retreatments could be reduced with sustained visual results. 
PIER study (16) analyzed a treatment protocol of three consecutive monthly injections of 
ranibizumab, followed by injections every three months. The results of this study were 
inferior when compared to the results achieved by the MARINA and ANCHOR trials, in 
particular between 3rd and 12th month when injections were given quarterly. 
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In PRONTO study (17) patients received 3 injections of ranibizumab on a monthly basis and 
thereafter as needed, based on strictly defined criteria, which included visual acuity decline, 
reoccurrence of fluid and central retinal thickness increase measured by OCT and clinical 
manifestation of macular hemorrhage. The results obtained by the PRONTO study were 
comparable to those of the MARINA and ANCHOR studies, but the number of injections 
required was lower: 5 injection of ranibizumab in the PRONTO versus 12 injections in the 
MARINA and the ANCHOR per year. 
SAILOR study (18) was designed with the purpose of confirming the results obtained by the 
PRONTO study. The SAILOR study lasted for 12 months. After three monthly injections of 
ranibizumab the additional injections were given based on predefined criteria, similar to 
those applied in the PRONTO study. The results of the SAILOR study were better than the 
ones of the PIER study, but not as good as those of the MARINA and ANCHOR, where 
injections were given on a monthly basis. The rate of the systemic side effects indicated a 
satisfactory safety profile. 
SUSTAIN study (19) confirmed the results given by the SAILOR study. The SUSTAIN study 
achieved better results than the PIER study, but inferior to those of the MARINA and 
ANCHOR and the PRONTO studies. During a 1-year follow-up period, mean number of 
injections applied was around 5 and visual acuity improved by 3.6 letters. Central retinal 
thickness was reduced by 92 microns. 
The HORIZON study (20) was a sequel to the MARINA and ANCHOR studies, its main 
purpose was to analyze the long term follow-up results and furthermore, to switch from 
monthly dosing to dosing as needed and to observe an impact on visual acuity. Additional 
treatment was required in more than 60% of patients during the 2 year follow-up period. 
Visual gain achieved after two years of monthly injections of ranibizumab was not 
maintained with less frequent dosing of ranibizumab.  
The monthly dosing remained, however, the best way to preserve the visual acuity. Any 
reduction in number of injections led to inferior visual outcome. Due to frequent dosing and 
other paramedical factors, regular monthly drug application presented a great burden to 
substantial number of patients. 
3.1.3 Bevacizumab 
Bevacizumab (Avastin) is a humanized recombinant monoclonal mouse antibody. A 
molecular weight of bevacizumab is 149 kilodaltons. It is active against all VEGF-A 
isoforms. Bevacizumab has been approved as an intravenous drug in the treatment of 
metastatic colon cancer (21), along with chemotherapy. It helps to induce the reduction of 
the tumor volume by deprivation of tumor vascularization (22). 
In 2005, bevacizumab was administered as ocular treatment for the first time. First 
bevacizumab trial included 9 patients with nAMD. Bevacizumab was given intravenously 
(5mg/kg) at two week intervals resulting in 12-letters gain with a significant reduction of 
intraretinal macular edema at the 12 week follow-up period (23). 7 patients experienced 
mild hypertension as a side-effect. 
Due to systemic side-effects (hypertension, gastrointestinal bleeding, thromboembolic 
events), bevacizumab was then applied intravitrealy in a concentration of 1 mg/0.1 ml, 
which was a significantly lower dose compared to the systemic one, while the good visual 
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outcome was maintained (24). Despite its large molecular weight, bevacizumab showed 
satisfying penetration into subretinal space, without any harmful neurophysiologic effects 
(25). Many clinical trials confirmed later the efficacy of bevacizumab in improving the visual 
acuity, reducing the retinal exudation and the acceptable safety profile (26,27,28,29,30).  
Bevacizumab and ranibizumab exhibit differences and similarities in the treatment of 
nAMD: 
• Both drugs inhibit all VEGF-A isoforms. 
• Bevacizumab has weaker affinity towards the VEGF factor than ranibizumab. 
• Bevacizumab has larger molecular weight, which could interfere with the penetration 
ability. 
• Given that the bevacizumab is a full antibody with the Fc fragment, whereas 
ranibizumab is only an antibody fragment, it might be more immunogenic. 
Several studies showed no difference in efficiency between ranibizumab and 
bevacizumab(31,32,33). Interesting results came from a study which concluded that 
functional result were alike, however bevacizumab needed a longer period of time to 
achieve resolution of retinal edema than ranibizumab: 60 versus 90 days. The period of the 
drug potency was 110 days for bevacizumab, and 70 days for ranibizumab, suggesting a 
longer interval of bevacizumab dosing(34).  
Comparison of AMD Treatment Trials (CATT) study (35) was designed to compare 
ranibizumab and bevacizumab in treatment of nAMD. 1208 patients were enrolled. Patients 
were randomized into four study arms: ranibizumab monthly or as needed and 
bevacizumab monthly or as needed. Ranibizumab and bevacizumab showed equivalent 
results in terms of efficiency. Patients treated with monthly bevacizumab gained 8 letters, 
while patients treated with monthly ranibizumab gained 8.5 letters after 12 month follow-up 
period. In as-needed arms bevacizumab was equivalent to ranibizumab with 5.9 and 6.8 
letters gained. 
Ranibizumab as needed was equivalent to monthly ranibizumab, while comparison 
between bevacizumab as needed and bevacizumab monthly showed inconclusive results. 
Rates of death, myocardial infarction, and stroke were similar for patients receiving either 
ranibizumab or bevacizumab. The proportion of patients with serious systemic adverse 
events (SSAE) requiring hospitalization was higher with bevacizumab than with 
ranibizumab arms (24.1% vs.19.0%). The importance of the CATT trial was in reporting the 
same efficacy of bevacizumab in a major randomized clinical trial. The raised concern with 
higher incidence of SSAE in bevacizumab is worth of noting but still inconclusive and needs 
to be further analyzed. 
4. Drugs under investigation 
4.1 VEGF Trap Eye (aflibercept) 
To initiate molecular mechanism of neovascularization, it is essential for the VEGF to bind 
to endothelial cell receptors VEGFR1 and VEGFR2, which act as transmembrane tyrosine 
kinases. 
By binding VEGF to their outer subunit, tyrosine kinase is activated which then triggers 
intracellular signaling pathways. The VEGF Trap Eye is a fusion protein containing VEGFR1 
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and VEGFR2 similar domains combined with Fc immunoglobulin segment (36). This means 
that VEGF Trap Eye has antibody inhibiting characteristics for all VEGF-A isoforms and 
binding affinity 800 times greater than bevacizumab. A clinical trial with 25 patients has 
shown good tolerability and increased visual acuity 6 weeks after single intravitreal 
injection (37). 
VIEW 1 and VIEW 2 were phase III, randomized, double- masked, clinical trials (38,39) 
evaluating VEGF Trap Eye effect on maintaining and improving vision as compared to 
ranibizumab.The studies have been completed in 2011. VIEW 1 was conducted in USA and 
VIEW 2 was conducted in Asia, Europe, Japan and Latin America. In both studies patients 
were randomized evenly to one of four treatment groups:0.5 mg ranibizumab monthly, 
VEGF trap 0.5 mg monthly, VEGF trap 2 mg monthly or VEGF trap 2 mg dosed every 8 
weeks following a tree-injection loading dose. 
VIEW 1 enrolled 1217 patients. Prevention of moderate vision loss was achieved in 94-96% 
of patients from all four groups showing VEGF Trap Eye non inferior to ranibizumab. Mean 
gain in visual acuity in all four groups was as follow: VEGF Trap 0.5 mg group achieved a 
mean gain of seven letter, the 2 mg VEGF Trap montly group a mean gain of 11 letters, the 2 
mg VEGF Trap dosed every two months after initial loading dose gained a mean of 8 letters 
while ranibizumab monthly group gained a mean of 8 letters. The only statistically 
significant difference in visual gain was between patients receiving VEGF Trap Eye 2mg 
monthly compared to ranibizumab monthly with p<0.01 (11 letter vs. 8 letter gain at week 
52) showing superiority of VEGF Trap Eye dosed 2mg monthly.  
International VIEW 2 study enrolled 1240. As in VIEW 1 study, prevention of moderate 
vision loss was achieved in 94- 96 percent of patients from all four groups confirming non 
inferiority of VEGF Trap Eye at all doses compared to monthly ranibizumab. 
A generally favorable safety profile was observed for both VEGF Trap Eye and 
ranibizumab. The most frequent ocular adverse events were conjunctival hemorrhage, 
macular degeneration, eye pain, retinal hemorrhage, and vitreous floaters.  
In conclusion both VIEW 1 and VIEW 2 studies showed VEGF-Trap-Eye being non inferior 
to monthly ranibizumab in prevention of moderate vision loss with good safety profile and 
potential for VEGF-Trap to achieve equally superior visual results as monthly ranibizumab 
with less frequent dosing. When dosed 2 mg monthly VEGF Trap Eye even showed superior 
in terms of vision gain compared to ranibizumab monthly 
4.2 Interfering RNA 
Small interfering RNAs (siRNA) are synthetic nucleotide chains, containing 20 nucleotides. 
While VEGF antibodies neutralize the already produced VEGF, siRNA interferes with  
VEGF -A messenger RNA (mRNA)(40,41), inhibiting thereby the production of all VEGF-A 
isoforms. 
As a result, the already produced VEGF persists within the eye for a couple of the first 
treatment weeks, leading to delayed therapeutic effect. 
SiRNA 027 interferes with the VEGF-R1 mRNA production. As demonstrated by CNV 
models, intravitreal and periocular injection of siRNA resulted in a significant CNV lesion 
reduction (42). 
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Other siRNA target hypoxia-induced transcription factor (HIF-1).  This factor is important 
not only in tumor angiogenesis but also in normal vessel formation. HIF-1 is composed of 
the constitutively expressed HIF-1 beta subunit and the 3-alfa subunit. In non-hypoxia 
conditions, HIF-1 alpha dissolves rapidly, whereas in the hypoxic environment, HIF-1 alpha 
becomes stable and acts as a hypoxia-provoked inducible gene regulator (43). Currently 
there are no ongoing clinical trials investigating this compound in treatment of nAMD but 
data from previous studies showed the compound to have a potential for VEGF inhibition. 
4.3 Tyrosine kinase inhibitors 
One of the most important biochemical mechanisms of intracellular signaling mediation is 
reverse phosphorilation. This reaction is catalysed by kinase proteins, which transfer g-
phosphate ATP group to hydroxyl group of targeted proteins (44). There are 518 of such 
proteins in human genome, 90 of which are selective hydroxyl group tyrosine 
phosphorilation catalysts(45).  
Cytosol tyrosine kinases are intracellular, while the receptor tyrosine kinase (RTK) have 
intracellular and extracellular domain and function as membrane receptors. The RTKs 
modulate cellular responses as such to signalling from the environment and act as various 
cell processes boosters of cellular proliferation, migration and survival. Otherwise the RTK 
signal mechanisms are well regulated, while their excessive activation can stimulate growth, 
survival and tumor cell metastasis development (46). Members of the VEGF and PDGF 
receptor group, which belong to the RTK family, promote tumor progression through 
various mechanisms: angiogenesis, limphangenesis and vascular permeability. 
PTK 787 is a RTK inhibitor with binding affinity to VEGF receptor tyrosine kinase and thus 
inhibits all VEGF-A isoforms. PTK 787 displayed functional improvement of ischemic 
retinopathy induced in mice. A single intravitreal injection of PTK reduced angiproliferative 
changes compared to the control eye of each animal (n=37) when retinopathy scores were 
compared (47). Currently there are no clinical trials of PTK 787 in treatment of nAMD, but 
the compound has a potential for VEGF inhibition. 
4.4 Cytokine PEDF 
Pigment Epithelial Derived Factor (PEDF), produced by retinal pigment epithelial cells is 
one of the most important endogenous angiogenesis inhibitors (48). The exact location of the 
PEDF production is on the apical side of pigment epithelial cells and contrary to VEGF it is 
inhibited by hypoxia. 
A high PEDF concentration can be found in extracellular photoreceptor matter, vitreous and 
cornea, indicating its major role in maintaining the tissues avascularity (49). The PEDF’s 
anti-angiogenic capacity has been proven in laser-stimulated CNV animal model (50). The 
PEDF concentrations are lower in the eyes suffering from CNVs, which is consistent with its 
anti-angiogenic properties. Therefore gene transferring adenovirus coding over-expression 
of PEDF could suppress the angiogenesis process. 
4.5 Epimacular brachytherapy 
Previously used, radiation therapy from external radiation source produced inconsistent 
results with high rate of side-effects. It was therefore abandoned from everyday clinical 
practice. Localized radiation treatment, on contrary has an ability to prevent proliferation of 
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vascular tissue by inhibiting neovascularization (51,52). After low-dose radiation, vascular 
endothelium demonstrates morphologic and DNA changes, inhibition of replication, 
increased cell permeability, and apoptosis. Fibroblast proliferation and subsequent scar 
formation, a hallmark of end-stage nAMD are also inhibited.  
CNVs which contain proliferating endothelial cells due to the hypoxic environment and the 
produced chemokines are more sensitive to radiation treatment than the retinal vasculature 
and non-proliferating capillary endothelial cells and larger vessels. Therefore to reduce 
complication rate and to improve visual outcome epimacular brachytherapy was introduced. 
It uses strontium-90 beta radiation as radiation source (NeoVista, Fremont, CA.). Total 
radiation dose is 24 gy. Epimacular brachytherapy is designed to deliver precisely controlled 
dose of beta radiation to CNV lesion. Compared to previously used radiation therapy 
strontium-90 beta radiation is ideal for treating retina because its delivery system ensues no 
collateral damage to surrounding retinal tissues (53,54). After pars plana vitrectomy is done, 
radiation applicator is placed directly above CNV lesion and held for 2-4 minutes. This has a 
dual effect: vitrectomy increases retinal oxygen saturation and in contrast to external beam 
radiotherapy a larger dose of radiation can be delivered to the macula with less irradiation of 
normal ocular structures and surrounding tissues. This novel device is currently being 
evaluated in two prospective, randomized, controlled trials in treatment-naive subjects: the 
CNV Secondary AMD Treated with Beta Radiation Epretinal Therapy  (CABERNET) and in 
subjects already treated with anti-vascular endothelial growth factor therapy: Macular 
Epiretinal Brachytherapy versus Lucentis Only Treatment (MERLOT). 
4.6 Combination treatment 
Having in mind the multiplicity of signaling mechanisms which are crucial for the 
development of nAMD as well as multistage evolution of the disease, combination 
treatments could have synergistic effect in halting the progression of disease. 
The anti-VEGF and PDT with verterpofin have up to now been the only available options 
mostly used in everyday clinical practice. The introduction of the PDT in treatment of 
nAMD in 2001 for the very first time affected natural course of the disease. This was 
achieved by acting on the last arm in pathophysiologic cascade of neovascularisation 
process: destruction of already formed neovascular membrane.  
The second major breakthrough in the therapy of nAMD was the introduction of anti-VEGF 
drugs. 
The anti-VEGF drugs act one step earlier in pathogenesis of the disease opposite to PDT, by 
preventing neovascularization and inducing regression of the newly formed neovascular 
blood vessels still dependent on VEGF support. Unlike PDT, which could only slow down 
the disease progression and reduce the visual acuity decline, patients treated with anti-
VEGF could expect their visual acuity to be maintained and even improved in significant 
number of patients. 
Although the anti-VEGF drugs are for the time being the best treatment option in managing 
nAMD, there are a few setbacks that caused the initial enthusiasm to drop. Regardless of 
anti-VEGF frequent dosing, a significant number of patients suffer further visual acuity 
deterioration throughout the course of the disease. Frequent intravitreal applications raise a 
risk for local complications such as: endophthalmitis, uveitis, vitreous hemorrhage, retinal 
detachment, posterior vitreous detachment etc. Despite continuous anti-VEGF blockage, 
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active signaling pathways and  expression of VEGF genes lead to continuous VEGF 
production, so continuous and regular treatment over a longer period of time is required as 
anti-VEGF drugs block only already produced VEGF. 
Besides already mentioned increased complication risks, another problem is cost of anti-
VEGF drugs as well as discomfort caused by intravitreal mode of application which 
ultimately leads to poor patient compliance. Having this in mind, new treatment options 
should be investigated. A potential new therapy regimen should actually have the following 
characteristics: 
1. Increased treatment efficacy. 
2. Prolonged remission period. 
3. Low reapplication rate. 
4. Low complications rate. 
5. Acceptable cost. 
6. Comfortable mode of administration. 
In pursuit of better treatment modality in 2006 we proposed a combination of PDT and anti-
VEGF with an idea to address two different steps of CNV formation: VEGF induced 
neovascularization and destruction of already formed CNV. In future a third potential drug 
acting on gene transcription could also be included thus preventing revascularization even 
earlier in the cascade of events. Further experimental and clinical trials are needed to 
support this hypothesis. 
Clinical studies conducted between 2001 and 2006, i.e. before the introduction of anti-VEGF 
drugs, investigated a possibility of a combination treatment for nAMD using PDT and 
trimacinolone. Trimacinolone is a long-acting corticosteroid, otherwise employed in 
treatment of rheumatic diseases of locomotor system. In ophthalmology trimacinolone was 
used intravitreally for diabetic macular edema. A significant number of studies 
demonstrated the same functional outcome of triamcinolone and PDT combined versus the 
PDT alone, with longer remission interval and a reduced need for additional reapplications 
of PDT when combined with triamcinolone(55,56,57,58). Since the combination therapy of 
triamcinolone and PDT proved to have synergistic effect, we hypothesized that combination 
of anti-VEGF drugs and PDT could either improve functional outcome or extend treatment 
intervals in patients with nAMD. We suggested a possible synergistic effect due to different 
target-points of choroidal neovascularization process: PDT inducing vascular occlusion to 
already formed neovascular vessels while anti-VEGF drugs preventing formation of new 
neovascular tissue, inducing regression of the newly formed VEGF-dependent vessels and 
reducing permeability of neovascular tissue. Additional production of VEGF after PDT-
induced hypoxia of choriocapilaris and inflammatory reaction due to neovascular tissue 
destruction could also be targeted with anti-VEGF drugs. In 2006, we concluded a pilot 
study on a small number of patients, divided into three groups - one treated with PDT, one 
with bevacizumab and the last one with bevacizumab and PDT together. The achieved 
results indicated possible synergistic effect: the visual acuity was better in patients who 
underwent combination therapy than in monotherapy groups, whereas the remission period 
was longer in combination group (59). 
Other studies also indicated possible amplifying effect of the combination treatment with 
PDT and anti-VEGF. Also some studies included addition of intravitreal corticosteroid to 
address the inflammatory component of the disease (60-70). 
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The RADICAL was a phase II, multicentric, randomized, single-masked study of 162 patients 
with nAMD. The purpose of the study was to determine whether the PDT combined with 
ranibizumab reduced re-treatment rate compared with ranibizumab monotherapy. Patients 
were randomized into 4 groups: ranibizumab monotherapy, triple therapy with quarter-
fluence verteporfin followed by ranibizumab and then dexamethasone, triple therapy with 
half-fluence verteporfin followed by ranibizumab and then dexamethasone and double 
therapy with half-fluence verteporfin followed by ranibizumab. The 24-month results showed 
significantly fewer retreatments in combination groups than in ranibizumab monotherapy 
group. Mean visual acuity change was not statistically different among the treatment groups. 
Through 24 months, patients in the triple therapy half-fluence group had a mean of 4.2 
retreatment visits compared with 8.9 for patients who received ranibizumab monotherapy.  
At the month 24, mean VA in the triple therapy half-fluence group improved 1.8 letters fewer 
compared with the ranibizumab monotherapy group which was not significantly inferior.  
This results show a potential of combination therapy in reducing the retreatment rate while 
sustaining the same visual outcome. The concept of combination therapy with new emerging 
drugs could further show a synergistic effect when those drugs would be combined. 
The displayed figures depict 2 patients from an extension of our pilot study throughout the 
period of 3 years. Both patients were treatment naïve. First patient N.U. was randomized to 
bevacizumab monotherapy treatment group and was treated with bevacizumab only and 
second patient R.K. was randomized to combination treatment group and was treated with 
combination treatment initially and then bevacizumab as needed. The second patient treated 
with combination treatment required less intravitreal bevacizumab injections during a 3 
year follow-up period. 
 
Fig. 1. Patient N.U. 76 yrs., fundus photography at baseline before bevacizumab treatment 
showing exudation and hemorrhage. 
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Fig. 2. Patient N.U. 76 yrs, early and late phase fluorescein angiography pictures at baseline 
before bevacizumab treatment showing blockage of retrofluorescence by hemorrhage, and a 
leakage of dye from the CNV. 
 
Fig. 3. Patient N.U. 76 yrs OCT scan (Zeiss Stratus II device) at baseline before bevacizumab 
treatment. It shows accumulation of intraretinal and subepithelial fluid. 
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Fig. 4. Patient N.U. 76 yrs, OCT scan (Optopol SD device). It shows the resolution of fluid 3 





Fig. 5. Patient R.K. 74 yrs., fundus photography at baseline before combination treatment 
(bevacizumab + PDT) showing exudation and hemorrhage. 
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Fig. 6. Patient R.K. 74 yrs, early and late phase of fluorescein angiography at baseline before 
combination treatment (bevacizumab+PDT). It shows marginal hemorrhage and leakage of 
dye from the CNV. 
 
 
Fig. 7. Patient R.K. 74 yrs OCT scan (Zeiss Stratus II device) at baseline before combination 
treatment. It shows accumulation of intraretinal and subretinal fluid. 
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Fig. 8. Patient R.K. 74 yrs OCT scan (Optopol SD device). It shows resolution of fluid 3 years 
after initial combination treatment of intravitreal bevacizumab and photodynamic therapy 
followed by repeated bevacizumab treatment. 
In summary we can conclude that new emerging therapies for nAMD for the first time in 
history managed to revert the natural history of disease. In significant number of patients 
some improvement could be achieved while in a majority of patients the treatment resulted 
in maintenance of visual acuity. However the significant burden of repeated intravitreal 
injections, increased risks of ocular and possibly systemic side effects and decreased 
patients’ compliance lead to further visual loss over time. Also some patients do not 
respond to the available treatments favorably. So the need for new and more efficient drugs 
in terms of better functional outcome and reduced need for retreatment is fully justified. 
VEGF-Trap-Eye is pending approval and it may show to be more potent and requiring less 
treatment. Also combination of present treatment modalities should further be evaluated. 
Hopefully with better understanding of the genes responsible for different variants of 
nAMD we could either employ some form of genetic therapy or we can adjust already 
available treatments according to a certain genotype in order to achieve most favorable 
results.   
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